Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07364305 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC

Name: HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC — clinical trial record (NCT07364305)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: Lalo

StatusRecruiting

PhasePhase 2

SponsorEastern Hepatobiliary Surgery Hospital

Started2025-01-01

View on ClinicalTrials.gov ↗

Eastern Hepatobiliary Surgery Hospital

15 trials monitored

See 1 trial at risk

Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis. The aim of this study is to investigate the efficacy and safety of GP-HAIC combined with immunosuppressants in the treatment of initially unresectable ICC patients, as well as its role in conversion therapy. A prospective study was conducted on the data of locally advanced unresectable ICC patients receiving GC-HAIC combined with immunosuppressive therapy, evaluating the treatment efficacy and safety.

Trial Details

NCT Number	NCT07364305
Lead Sponsor	Eastern Hepatobiliary Surgery Hospital
Conditions	ICC, Advanced Cancer
Enrollment	50 participants
Start Date	2025-01-01
Primary Completion	2028-01-01 (estimated)
Study Completion	2028-01-01 (estimated)
Updated on ClinicalTrials.gov	2026-01-23